Insights & Discussion
Discover Related Insights
Green tea helps alleviate symptoms in multiple benign gynecological disorders, primarily due to a compound called Epigallocatechin-3-gallate.
2023 Nutrients Green Tea and Benign Gynecologic Disorders: A New Trick for An Old Beverage? Hazimeh D, Massoud G, Parish M, Singh B, Segars J, Islam MS
Review Article EGCG Green Tea Period Pain
The paper reviews the role of the compound Epigallocatechin-3-gallate found in green tea, and its effects on various benign gynecological conditions. The compound is noted for its antioxidant and prooxidant qualities, allowing it to interact with multiple cellular pathways that are crucial for disease pathogenesis. The studied conditions include uterine fibroids, endometriosis, dysmenorrhea, adenomyosis, menopause, and polycystic ovary syndrome. The research accounts for the specific mechanisms through which the compound might affect each condition, such as anti-fibrotic, anti-angiogenic, and pro-apoptotic mechanisms.
The results suggest that green tea consumption can lead to improved symptom management in these disorders. It was found to lessen the intensity of symptoms associated with uterine fibroids and endometriosis, by invoking anti-fibrotic, anti-angiogenic, and pro-apoptotic mechanisms. It also helped manage pain linked with dysmenorrhea and adenomyosis through reducing uterine contractility and widely felt pain. Additionally, it showed efficacy in weight and osteoporosis control during menopause, and showed potential benefits in managing polycystic ovary syndrome. However, claims regarding its influence on fertility were deemed controversial.
Epigallocatechin gallate (EGCG), a green tea component, showed potential in treating uterine fibroids and associated infertility without causing liver toxicity or folate deficiency.
2023 Nutrients Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women Siblini H, Al-Hendy A, Segars J, González F, Taylor HS, Singh B, et al.
Cohort Study EGCG Green Tea Uterine Fibroids
The study involved the pre-testing of a green tea substance known as Epigallocatechin gallate (EGCG) on a cohort of premenopausal women, aged 18 to 40, with and without uterine fibroids, in order to evaluate its safety. The subjects were randomized into three groups, each receiving different treatments. One group took just a daily dose of 800 mg of EGCG, one group combined this EGCG dose with 100 mg of Clomiphene citrate for five days, and the third group combined it with 5 mg of Letrozole for the same period.
The results showed that none of the subjects displayed signs of drug-induced liver injury, and all had normal serum folate levels. Hence, the findings suggest that the daily intake of 800mg of EGCG, whether consumed alone or in combination with Clomiphene citrate or Letrozole for five days, is well-tolerated and not related to any liver toxicity or folate deficiency in women of reproductive age.
Combining Crila with green tea extract (EGCG) has been found to synergistically hinder the growth of human uterine fibroid cells.
2023 F&S Science The combination of natural compounds Crila and epigallocatechin gallate (EGCG) showed enhanced antiproliferative effects on human uterine fibroid cells compared to single treatments. Bai T, Ali M, Somers B, Yang Q, McKinney S, Al-Hendy A
Network Pharmacology EGCG Uterine Fibroids
In the methodological process, human uterine leiomyoma (HuLM) cells were treated with varying concentrations of Crila, either alone or combined with epigallocatechin gallate (EGCG), employing various tests. Prominently, assays were performed to examine cell proliferation, with additional analyses conducted to measure protein and gene expressions of proliferation markers.
The interaction of Crila and EGCG resulted in a notable reduction in HuLM cell viability, showing an increased inhibitory effect over singular treatments. This decrease in cell proliferation is attributed to a synergistic efficacy derived from using Crila and EGCG in combination. It was notably characterised by the reduced presence of the proliferation marker, proliferating cell nuclear antigen, both at the messenger RNA and protein levels. It was observed that the process does not induce cell apoptosis, implying that the cell viability reduction is primarily due to decreased cell proliferation.
The combination of epigallocatechin gallate, vitamin B12, folic acid, and hyaluronic acid could effectively counter precancerous lesions of the uterine cervix caused by HPV infections.
2023 Journal of Personalized Medicine The Association of Four Natural Molecules—EGCG, Folic Acid, Vitamin B12, and HA—To Counteract HPV Cervical Lesions: A Case Report Grandi G, Botticelli L, Fraia PD, Babalini C, Masini M, Unfer V
Case Report Cervical Cancer Cervical Dysplasia Cervical Lesions
The methodology used in this research centred around treating a 39-year-old patient who had a history of HPV, cervix lesions, and multiple failed surgical attempts to treat the condition. The treatment plan applied was unique, utilizing a blend of epigallocatechin gallate, vitamin B12, folic acid, and hyaluronic acid, administered over an eight week period.
The results showed promising effects, with the patient's histological and cytological analyses revealing only a chronic cervicitis instead of any malignant lesions or cellular dysplasia. Therefore, the necessity for invasive total hysterectomy was minimized, demonstrating the potential for the selected treatment plan to manage precancerous lesions of the uterine cervix.
A combination of epigallocatechin gallate, folic acid, vitamin B12, and hyaluronic acid may effectively clear HPV infections and cervical lesions in women.
2023 Journal of Clinical Medicine Evaluating the Efficacy of Pervistop®, a New Combination Based on EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid on Patients with Human Papilloma Virus (HPV) Persistent Infections and Cervical Lesions: A Pilot Study Aragona C, Bezerra Espinola MS, Bilotta G, Porcaro G, Calcagno M
Randomised Controlled Trial Cervical Dysplasia EGCG Folic Acid
Forty women with persistent HPV infections and cervical lesions were enrolled in this study and were then divided into two groups. Women in the treatment group were given a 12-week treatment comprising of 200mg epigallocatechin gallate, 400µg folic acid, 1mg vitamin B12, and 50mg hyaluronic acid. In contrast, the control group received no treatment.
A significant difference was noted between the two groups post-treatment. In the control group, the majority of women still had a Low-Grade Squamous Intraepithelial Lesion (LSIL) at the close of the study, with varying changes in viral DNA content. However, in the case of the treated group, most women had achieved full viral clearance, showing no signs of lesions post-treatment, thus highlighting the potential effectiveness of the treatment combination.
Sign In
Users not signed in are limited to viewing the 5 most recent items of content.